News | Heart Valve Technology | May 24, 2016

Sapien 3 Transcatheter Valve Demonstrates Positive Patient Outcomes at 30 Days

More than half of patients in European post-approval study treated with conscious sedation

Edwards, Sapien 3, SOURCE 3 Registry, EuroPCR 2016

May 24, 2016 — Thirty-day data from the European post-approval study of the Edwards Sapien 3 transcatheter aortic heart valve demonstrated positive patient outcomes, including the lowest reported mortality and stroke rates seen in the SOURCE family of registries.

The new data were presented at EuroPCR 2016 by Olaf Wendler, M.D., Ph.D., professor of cardiothoracic surgery at King's College Hospital, London.

The SOURCE 3 Registry, a monitored and adjudicated prospective registry, is studying use of the low-profile Edwards Sapien 3 valve in a real-world commercial setting, treating patients with severe, symptomatic aortic stenosis. Patients treated via the transfemoral access route had a high survival rate of 98.1 percent at 30 days. Additionally, the study found a low stroke rate of 1.2 percent in transfemoral patients.

"The high survival and low stroke rates seen in the SOURCE 3 Registry with the Sapien 3 valve confirm the positive impact TAVR [transcatheter aortic valve replacement] provides in the real-world setting," Wendler said. "These results give us confidence that the excellent outcomes seen in early clinical trials using the Sapien 3 are reproducible by heart teams in routine practice." 

Data from the SOURCE 3 Registry documented the outcomes of 1,947 patients treated at 80 centers in Europe performing TAVR. Patients were enrolled in 10 countries between July 2014 and October 2015 and will be followed for five years. This represents the first large, multi-center report of Sapien 3 valve patient outcomes in a commercial setting, as well as the largest dataset of patients who were treated using conscious sedation with a singular valve platform (1,018 patients). Patients treated under conscious sedation are awake during the procedure and do not receive general anesthesia.

The Edwards Sapien 3 valve has been available in Europe since 2014.

Wendler is a consultant to Edwards Lifesciences.

For more information:

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Overlay Init